Publication:
Glofitamab in relapsed/refractory diffuse large b-cell lymphoma: Real-world data

dc.contributor.authorAteşoğlu, Elif Birtaş
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorUzay, Ant
dc.contributor.authorÖzcan, Muhit
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKalyon, Hakan
dc.contributor.authorAkay, Olga Meltem
dc.contributor.authorDeveci, Burak
dc.contributor.authorBekoz, Hüseyin
dc.contributor.authorSevindik, Ömür Gökmen
dc.contributor.authorToptaş, Tayfur
dc.contributor.authorYılmaz, Fergün
dc.contributor.authorKoyun, Derya
dc.contributor.authorAlış, Nihan
dc.contributor.authorAlacacıoğlu, Inci
dc.contributor.authorSönmez, Mehmet
dc.contributor.authorYavaşoğlu, Irfan
dc.contributor.authorTombak, Anıl
dc.contributor.authorMehtap, Özgür
dc.contributor.authorKurnaz, Fatih
dc.contributor.authorYüce, Orhan Kemal
dc.contributor.authorKarakuş, Volkan
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorKürekci, Derya Deniz
dc.contributor.authorAyer, Mesut
dc.contributor.authorKeklik, Muzaffer
dc.contributor.authorBüyüktas, Deram
dc.contributor.authorÖzbalak, Murat
dc.contributor.authorFerhanoglu, Burhan
dc.contributor.buuauthorÖzkalemkaş, Fahir
dc.contributor.buuauthorÖZKALEMKAŞ, FAHİR
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.researcheridDLR-8474-2022
dc.date.accessioned2024-12-03T05:39:50Z
dc.date.available2024-12-03T05:39:50Z
dc.date.issued2023-05-22
dc.description.abstractGlofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients with relapsed/refractory (R/R) B-cell lymphoma. However, the real-world data of patients of all ages with no strict selection criteria are still lacking. Herein, this retrospective study aimed to evaluate the outcomes of diffuse large B-cell lymphoma (DLBCL) patients who received glofitamab via compassionate use in Turkey. Forty-three patients from 20 centers who received at least one dose of the treatment were included in this study. The median age was 54 years. The median number of previous therapies was 4, and 23 patients were refractory to first-line treatment. Twenty patients had previously undergone autologous stem cell transplantation. The median follow-up time was 5.7 months. In efficacy-evaluable patients, 21% and 16% of them achieved complete response and partial response, respectively. The median response duration was 6.3 months. The median progression-free survival (PFS) and overall survival (OS) was 3.3 and 8.8 months, respectively. None of the treatment-responsive patients progressed during the study period, and their estimated 1-year PFS and OS rate was 83%. The most frequently reported toxicity was hematological toxicity. Sixteen patients survived, while 27 died at the time of the analysis. The most common cause of death was disease progression. One patient died of cytokine release syndrome during the first cycle after receiving the first dose of glofitamab. Meanwhile, two patients died due to glofitamab-related febrile neutropenia. This is the largest real-world study on the effectiveness and toxicity of glofitamab treatment in R/R DLBCL patients. The median OS of 9 months seems promising in this heavily pretreated group. The toxicity related mortality rates were the primary concerns in this study.
dc.identifier.doi10.1002/hon.3174
dc.identifier.endpage673
dc.identifier.issn0278-0232
dc.identifier.issue4
dc.identifier.scopus2-s2.0-85159808449
dc.identifier.startpage663
dc.identifier.urihttps://doi.org/10.1002/hon.3174
dc.identifier.urihttps://hdl.handle.net/11452/48794
dc.identifier.volume41
dc.identifier.wos000991717000001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherWiley
dc.relation.journalHematological Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSingle-arm
dc.subjectOpen-label
dc.subjectMulticenter
dc.subjectBispecific antibodies
dc.subjectGlofitamab
dc.subjectRelapsed
dc.subjectRefractory diffuse large b-cell lymphoma
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectOncology
dc.subjectHematology
dc.titleGlofitamab in relapsed/refractory diffuse large b-cell lymphoma: Real-world data
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı
local.indexed.atWOS
local.indexed.atScopus
relation.isAuthorOfPublication6d4676a2-f825-4560-bfa8-c7eb6daf748d
relation.isAuthorOfPublication.latestForDiscovery6d4676a2-f825-4560-bfa8-c7eb6daf748d

Files